Travere Therapeutics, Inc. und Eric Dube, Ph.D., haben am 21. September 2026 im gegenseitigen Einvernehmen den Zeitplan und ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his ...
Travere Therapeutics (TVTX) said late Monday its president and chief executive officer Eric Dube has decided to step down to focus on his health and family. The board has unanimou ...
Le 21 septembre 2026, Travere Therapeutics, Inc. et Eric Dube, Ph.D., ont convenu d'un commun accord du calendrier et des modalités de la transition prévue du Dr Dube. Ce dernier quittera ...
Investing.com -- Le azioni di Travere Therapeutics Inc ( NASDAQ:TVTX) sono scese fino al 2,3% nelle contrattazioni ...
Travere Therapeutics named Bradley Campbell as president and chief executive officer, effective Dec. 1. Campbell's appointment comes as the biopharmaceutical company's president and CEO Eric Dube ...
Avviso esplicito sui rischi: Il trading degli strumenti finanziari e/o di criptovalute comporta alti rischi, compreso quello ...
Travere Therapeutics insider Inrig Jula exercised options for 32,395 shares at $8.93 each, followed by the sale of 44,674 ...
Janus Henderson Global Life Sciences Fund returned 12.80% and the MSCI World Health Care Index returned 6.75%.
On September 15, 2026, Travere Therapeutics CFO Cline Christopher R. exercised options for 20,000 shares at an exercise price ...
Travere Therapeutics was first featured on our site on August 14, 2024, when the stock was trading at $8.91. At the time, our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results